INCA000585

Phase 2Small molecule

Incyte

INCA000585 is one of 50 small molecule programs targeting Immune Thrombocytopenia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immune ThrombocytopeniaRecruiting

Immune ThrombocytopeniaPhase 2

Recruiting

Competition

Competitive Landscape

56 competitors in Immune Thrombocytopenia

#DrugCompanyPhaseTrials

Promacta

GSK

Approved

14 2

Rituxan

Roche

Approved

13 3

Decadron

AAspen Global Incorporated

Approved

21 4

Oncovin

Eli Lilly

Approved

1 5

Plaquenil

Jazz Pharmaceuticals

Approved

1 6

Rayos

RRoxane Laboratories

Approved

6 7

Imuran

LLegacy Health System

Approved

1 8

Vyvgart

Argenx

Phase 3

6 9

Doptelet

AAkarx

Phase 3

6 10

Wayrilz

GGenzyme, a Sanofi Company

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Immune Thrombocytopenia

NCT07104565

Clinical

Trials by Indication[1]

Immune Thrombocytopenia1 trial

A Phase 2a, Open-Label, Multicenter Study of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Recruiting· Incyte logo

Incyte·Phase 2·NCT07104565·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for INCA000585. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INCA000585 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INCA000585. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Incyte company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Incyte

INCA000585

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Immune Thrombocytopenia1 trial

References

Drug Info

Quick Facts

Related News